ASXL1

The ASXL1 gene plays a crucial role in regulating gene expression through chromatin remodeling and DNA methylation, influencing critical genes involved in development and cellular function. 

Mutations in ASXL1 are commonly associated with hematologic disorders like MDS, AML, and CMML, and are linked to poor prognosis, resistance to therapies, and abnormal cell proliferation.

What is ASXL1?

The ASXL1 gene encodes a protein involved in chromatin remodeling, a process that alters DNA packaging to regulate gene expression. 

Chromatin is a complex of DNA and proteins that packages DNA into chromosomes. The ASXL1 protein alters the structure of chromatin and helps control how tightly DNA is packaged. Tightly packed DNA reduces gene expression, while loosely packed DNA allows for higher gene activity.

ASXL1 influences gene activation or repression by modifying how tightly the DNA is packed. This protein controls important genes, like HOX genes, essential for proper development before birth by determining when they should be activated. 

Additionally, ASXL1 helps regulate genes through methylation, a process where small chemical groups called methyl groups are added to the gene's control regions. When a gene is methylated, it is turned off, but when it is not methylated, the gene is activated.

ASXL1 supports normal cellular functions by managing these processes.

Clinical Implications of ASXL1 Mutations

ASXL1 mutations are commonly found in hematologic disorders like myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). 

These mutations result in a dysfunctional ASXL1 protein that disrupts normal gene regulation and promotes abnormal cell growth. 

Clinically, ASXL1 mutations are associated with poor prognosis, higher disease progression rates, and resistance to standard therapies. These mutations impair blood cell formation and lead to proliferation of abnormal cells. 

Monitoring ASXL1 mutations helps clinicians assess prognosis, guide treatment decisions, and determine eligibility for clinical trials, ultimately improving patient outcomes.

Who Should Be Tested for ASXL1 Mutations?

Testing for ASXL1 mutations is particularly valuable for individuals who show symptoms of hematologic disorders, such as unexplained anemia, leukocytosis (high white blood cell count), or thrombocytopenia (low platelet count). 

Additionally, patients diagnosed or suspected to have MDS, AML, or CMML should undergo ASXL1 testing to confirm the diagnosis and guide treatment strategies. 

At-risk populations, such as those with a family history of hematologic disorders or older adults (since ASXL1 mutations increase with age), should also be considered for testing.

Test Procedure and Interpretation

ASXL1 mutation testing often uses bone marrow aspirate or blood (cfDNA) samples. Testing methods include PCR-based mutation detection (such as Sanger sequencing) and Next-Generation Sequencing (NGS).

While no special patient preparation is required, documenting medical history, including treatments, is important for accurate test interpretation.

Normal Results

The absence of ASXL1 mutations is considered normal. A low mutation burden (e.g., less than 10% of alleles) is also generally not concerning.

Clinical Implications of the Presence of ASXL1 Gene Mutations

Elevated ASXL1 mutation levels often indicate a poor prognosis, suggesting a higher likelihood of disease progression, relapse, or resistance to treatments. This information may help make decisions about more aggressive treatments or exploring clinical trials with novel therapies.

Clinical Implications of Decreased or Negative ASXL1 Levels

A lower mutation burden typically suggests a better prognosis and a higher chance of responding to standard therapies, such as chemotherapy or hypomethylating agents. 

However, negative results should not rule out other genetic abnormalities, and clinicians should consider additional testing to ensure a comprehensive diagnosis.

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.